论文部分内容阅读
目的研究减量化疗肝动脉栓塞治疗伴有梗阻性黄疸原发性肝癌的安全性及疗效。方法回顾性分析24例首选减量化疗肝动脉栓塞治疗的伴有梗阻性黄疸的原发性肝癌病例。患者均为单个肿瘤。结果 24例患者中位生存期为9.0月,1、2、3年的生存率分别为33.3%、22.2%、16.6%。单因素及多因素生存分析显示,肿瘤大小及AFP水平是生存时间影响因素(P<0.05),总胆红素水平不是影响生存的因素(P>0.05)。24例患者术前总胆红素水平平均为70.5μmol/L,术后1月33.2μmol/L,较术前明显下降(P=0.006)。所有患者均无严重并发症发生。结论首选减量化疗肝动脉栓塞治疗伴有梗阻性黄疸的原发性肝癌是安全、有效的。
Objective To study the safety and efficacy of reduced-dose chemotherapy of hepatic artery embolization in the treatment of primary liver cancer with obstructive jaundice. Methods A retrospective analysis of 24 patients with primary reduction of hepatocellular carcinoma accompanied by obstructive jaundice in the treatment of hepatic arterial embolism with the preferred reduction of chemotherapy. All patients were single tumors. Results The median survival time of 24 patients was 9.0 months. The survival rates at 1, 2 and 3 years were 33.3%, 22.2% and 16.6%, respectively. Univariate and multivariate survival analysis showed that tumor size and AFP level were the influencing factors of survival time (P <0.05), and total bilirubin level was not the factor influencing survival (P> 0.05). The average preoperative total bilirubin level in 24 patients was 70.5 μmol / L and 33.2 μmol / L in January, which was significantly lower than that before operation (P = 0.006). No serious complications occurred in all patients. Conclusion The preferred reduction of hepatic artery embolization in the treatment of primary liver cancer with obstructive jaundice is safe and effective.